Semaglutide Beyond Weight Loss: The Cardiovascular and Longevity Data
Semaglutide is known for dramatic weight loss. The SELECT trial showed it reduces cardiovascular events in people without diabetes. The longevity implications are significant.
Semaglutide (Wegovy, Ozempic) has dominated health media for its weight loss effects. But the cardiovascular and longevity case extends beyond the scale.
How GLP-1 agonists work
GLP-1 (glucagon-like peptide-1) is a hormone released from the gut after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. GLP-1 agonists like semaglutide activate GLP-1 receptors throughout the body.
The weight loss mechanism is primarily central — reducing appetite via hypothalamic GLP-1 receptors. But GLP-1 receptors are also found in the heart, kidneys, liver, and brain.
The SELECT trial
The SELECT trial, published in the New England Journal of Medicine in 2023, was a landmark. 17,600 adults with overweight/obesity and established cardiovascular disease (but without diabetes) were randomized to semaglutide vs placebo.
Results: semaglutide reduced the primary composite outcome (cardiovascular death, non-fatal MI, non-fatal stroke) by 20%. This was statistically significant and clinically meaningful — comparable to the best statin or antihypertensive trials.
This is the first large RCT showing a cardiovascular benefit for a weight loss drug in non-diabetic patients. And the benefit was independent of the degree of weight loss — suggesting direct cardiovascular effects beyond body weight reduction.
Emerging data on inflammation and neurodegeneration
Ongoing trials are examining semaglutide for non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and Parkinson's disease. GLP-1 receptors in the brain may mediate anti-inflammatory and neuroprotective effects.
Early Parkinson's data is particularly intriguing — a small trial showed slowed disease progression with a GLP-1 agonist.
The practical reality
Semaglutide injections are weekly. Side effects are primarily GI — nausea, which is why we include ondansetron (an anti-nausea medication) in our Longevity GLP-1 stack. The nausea is worst in the first 4–8 weeks and typically improves with dose titration.
The SELECT trial used 2.4mg weekly (the weight management dose). Many longevity physicians use lower doses for patients whose primary goal isn't weight loss.